Pinteon Therapeutics Overview
- Founded
- 2014
- Status
- Private
- Employees
- 7
- Latest Deal Type
- Series A
- Latest Deal Amount
- $17M
- Investors
- 1
Pinteon Therapeutics General Information
Description
Developer of a novel antibody intended to maintain brain health of the patients. The company's antibody interrupts the spread of toxic tau and protects and preserves brain function in patients suffering from neurodegenerative disease, enabling doctors to normalize aberrant disease processes and improve patient outcomes in these high unmet medical need indications.
Contact Information
Website
www.pinteon.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 1188 Centre Street
- Newton, MA 02459
- United States
+1 (917) 000-0000
Pinteon Therapeutics Timeline
Pinteon Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 31-Oct-2019 | $17M | 0000 | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 17-Aug-2017 | 0000 | 0000 | 000.00 | Completed | Startup |
Pinteon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Pinteon Therapeutics Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Martin Jefson Ph.D | Chief Executive Officer | ||
| Michael Ahlijanian Ph.D | Chief Scientific Officer | ||
| Larry Altstiel Ph.D | Chief Medical Officer |
Pinteon Therapeutics Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Jason Dinges Ph.D | Morningside Group | Board Member | 000 0000 |
| Jeffrey Ives Ph.D | Self | Chairman | 000 0000 |
| Westley Nolin Ph.D | Self | Board Member | 000 0000 |
Pinteon Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialPinteon Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Morningside Group | Venture Capital | Minority | 000 0000 | 000000 0 |